Search results
Results from the WOW.Com Content Network
Protein-bound paclitaxel, also known as nanoparticle albumin–bound paclitaxel or nab-paclitaxel, is an injectable formulation of paclitaxel used to treat breast cancer, lung cancer and pancreatic cancer, among others. Paclitaxel kills cancer cells by preventing the normal breakdown of microtubules during cell division.
[12] [11] Paclitaxel is in the taxane family of medications. [13] It works by interference with the normal function of microtubules during cell division. [11] Paclitaxel was isolated in 1971 from the Pacific yew and approved for medical use in 1993. [14] [15] It is on the World Health Organization's List of Essential Medicines. [16]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
CD20 antibody bound with the radioactive isotope, 90Y, induces radiation-dependent cell lysis. Non-Hodgkin's lymphoma and follicular lymphoma. Thrombocytopenia, neutropenia, anaemia, hypotension and secondary malignancies. Ipilimumab: IV: CTLA4 antibody that causes immune system-mediated lysis of the tagged cell: Unresectable or metastatic ...
In 2013, the U.S. Food and Drug Administration approved protein-bound paclitaxel (also known as nab-paclitaxel, sold as Abraxane) used with gemcitabine. This regimen may be less toxic—but perhaps less effective—alternative to FOLFIRINOX for treating late-stage pancreatic cancer.
Pages in category "Drugs developed by Bristol Myers Squibb" The following 68 pages are in this category, out of 68 total. This list may not reflect recent changes .
Paclitaxel trevatide (development codes NG1005 and GRN1005) is an experimental chemotherapy drug that is under development by Angiochem Inc, a Canadian biotech company. Phase II clinical trials have completed for several indications, and the company is preparing for phase III trials. [1] Paclitaxel trevatide is a paclitaxel-Angiopep-2 conjugate ...
It is highly bound to human plasma protein. Within a concentration range of 1-30 μM (0.87-26 μg/mL), the fraction unbound in plasma was less than 0.01. [7] Venetoclax is metabolized by CYP3A4/5 as proven by in-vitro studies. [7] Those using the drug should not consume grapefruit products because they contain CYP3A inhibitors. [7]